TPST

TPST

USD

Tempest Therapeutics Inc. Common Stock

$7.760-0.172 (-2.166%)

Цена в режиме реального времени

Healthcare
Биотехнология
Соединенные Штаты

График цен

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$7.932

Максимум

$7.975

Минимум

$7.658

Объем

0.00M

Фундаментальные показатели компании

Рыночная капитализация

28.3M

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

0.06M

Биржа

NCM

Валюта

USD

52-недельный диапазон

Минимум $5.356Текущая $7.760Максимум $49.27

Связанные новости

GlobeNewswire

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight

Просмотреть больше
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
Analyst Upgrades

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.

Просмотреть больше
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Analyst Upgrades

Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Lowers Price Target to $9

Scotiabank analyst George Farmer downgrades Tempest Therapeutics from Sector Outperform to Sector Perform and lowers the price target from $91 to $9.

Просмотреть больше
Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Lowers Price Target to $9
Analyst Upgrades

HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics from Buy to Neutral and maintains the price target from $16 to $16.

Просмотреть больше
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16
GlobeNewswire

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track

Просмотреть больше
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.